JAMP GRANISETRON TABLET
Valsts: Kanāda
Valoda: angļu
Klimata pārmaiņas: Health Canada
Produkta apraksts
(SPC)
13-01-2020
Daži šī produkta dokumenti pašlaik nav pieejami. Varat nosūtīt pieprasījumu mūsu klientu apkalpošanas dienestam, un mēs jums paziņosim, tiklīdz mēs tos varēsim iegūt.
Nosūtīt pieprasījumu.
Nosūtīt pieprasījumu.
Aktīvā sastāvdaļa:
GRANISETRON (GRANISETRON HYDROCHLORIDE)
Pieejams no:
JAMP PHARMA CORPORATION
ATĶ kods:
A04AA02
SNN (starptautisko nepatentēto nosaukumu):
GRANISETRON
Deva:
1MG
Zāļu forma:
TABLET
Kompozīcija:
GRANISETRON (GRANISETRON HYDROCHLORIDE) 1MG
Ievadīšanas:
ORAL
Vienības iepakojumā:
15G/50G
Receptes veids:
Prescription
Ārstniecības joma:
5-HT3 RECEPTOR ANTAGONISTS
Produktu pārskats:
Active ingredient group (AIG) number: 0123183001; AHFS:
Autorizācija statuss:
APPROVED
Autorizācija datums:
2018-02-02
Produkta apraksts
PRODUCT MONOGRAPH
Pr
JAMP Granisetron
Granisetron Hydrochloride Tablets
1 mg granisetron (as granisetron hydrochloride)
Manufacturer Standard
Antiemetic
(5-HT
3
receptor antagonist)
Jamp Pharma Corporation
1310 rue Nobel
Boucherville, Québec
Canada J4B 5H3
Submission Control No.: 234371
DATE OF REVISION:
January 13, 2020
JAMP Granisetron
Page 2 of 25
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
..................................................................................................3
WARNINGS AND PRECAUTIONS
.................................................................................4
ADVERSE REACTIONS
..................................................................................................6
DRUG INTERACTIONS
..................................................................................................9
DOSAGE AND
ADMINISTRATION................................................................................9
OVERDOSAGE
..............................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 10
STORAGE AND
STABILITY.........................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 13
PART II: SCIENTIFIC
INFORMATION............................................................................
14
PHARMACEUTICAL
INFORMATION..........................................................................
14
CLINICAL TRIALS
........................................................................................................
14
DETAILED PHARMACOLOGY
..........
Izlasiet visu dokumentu
